Literature DB >> 8590733

Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter.

J S Harms1, G A Splitter.   

Abstract

The use of mammalian gene expression vectors has become increasingly important for transgenics and gene therapy as well as basic research. Essential for the success of these vectors in medical research applications is the proper choice of promoter linked to the gene of interest. Many mammalian expression vectors use promoter elements from pathogenic viruses, including simian virus 40 (SV40) and cytomegalovirus (CMV). Lymphokines produced by the immune response to proteins expressed by these vectors could inhibit further transcription initiation by viral promoters. Our objective was to determine the effect of interferon-gamma (IFN-gamma) on transgene expression driven by a viral SV40 or CMV promoter/enhancer and the mammalian promoter/enhancer for the major histocompatibility complex class I (MHC I) gene. We transfected the luciferase gene driven by these three promoters into 14 cell lines of many tissues and several species. Luciferase assays of transfected cells untreated or treated with IFN-gamma indicated that, although the viral promoters could drive luciferase production in all cell lines tested to greater or lesser levels than the MHC I promoter, treatment with IFN-gamma caused inhibition of transgene expression in most of the cell lines and amplification of the MHC I promoter-driven transgene expression in all cell lines. These data indicate that the SV40 and CMV promoter/enhancers may not be a suitable choice for gene delivery especially for immune response applications or in patients where IFN levels may be elevated. The MHC I promoter/enhancer, on the other hand, may be an ideal transgene promoter for applications involving the immune system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590733     DOI: 10.1089/hum.1995.6.10-1291

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  24 in total

Review 1.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

Review 3.  Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals.

Authors:  David A Dean
Journal:  Am J Physiol Cell Physiol       Date:  2005-08       Impact factor: 4.249

4.  Interferon gamma decreases intestinal epithelial aquaporin 3 expression through downregulation of constitutive transcription.

Authors:  Michael A Peplowski; Michael Dicay; Cristiane H Baggio; Filip Wysokinski; Bernard Renaux; Morley D Hollenberg; David Proud; Wallace K MacNaughton
Journal:  J Mol Med (Berl)       Date:  2018-08-08       Impact factor: 4.599

5.  High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments.

Authors:  K E Pollok; H Hanenberg; T W Noblitt; W L Schroeder; I Kato; D Emanuel; D A Williams
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy.

Authors:  S Ghazizadeh; J M Carroll; L B Taichman
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  Variation in adenovirus transgene expression between BALB/c and C57BL/6 mice is associated with differences in interleukin-12 and gamma interferon production and NK cell activation.

Authors:  Y Peng; E Falck-Pedersen; K B Elkon
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Polyplex exposure inhibits cell cycle, increases inflammatory response, and can cause protein expression without cell division.

Authors:  Rebecca L Matz; Blake Erickson; Sriram Vaidyanathan; Jolanta F Kukowska-Latallo; James R Baker; Bradford G Orr; Mark M Banaszak Holl
Journal:  Mol Pharm       Date:  2013-03-21       Impact factor: 4.939

9.  The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.

Authors:  Jacob J Elmer; Matthew D Christensen; Sutapa Barua; Jennifer Lehrman; Karmella A Haynes; Kaushal Rege
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

10.  Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Authors:  Moein Jafari; John Guatelli; Mary K Lewinski
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.